CN103313694B - O/W emulsion composition - Google Patents
O/W emulsion composition Download PDFInfo
- Publication number
- CN103313694B CN103313694B CN201180054795.9A CN201180054795A CN103313694B CN 103313694 B CN103313694 B CN 103313694B CN 201180054795 A CN201180054795 A CN 201180054795A CN 103313694 B CN103313694 B CN 103313694B
- Authority
- CN
- China
- Prior art keywords
- emulsion composition
- acid
- ether
- fatty acids
- higher fatty
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/06—Emulsions
- A61K8/062—Oil-in-water emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/342—Alcohols having more than seven atoms in an unbroken chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/361—Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
- A61K8/442—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof substituted by amido group(s)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/676—Ascorbic acid, i.e. vitamin C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
- A61K8/8105—Compositions of homopolymers or copolymers of unsaturated aliphatic hydrocarbons having only one carbon-to-carbon double bond; Compositions of derivatives of such polymers
- A61K8/8111—Homopolymers or copolymers of aliphatic olefines, e.g. polyethylene, polyisobutene; Compositions of derivatives of such polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/86—Polyethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/89—Polysiloxanes
- A61K8/891—Polysiloxanes saturated, e.g. dimethicone, phenyl trimethicone, C24-C28 methicone or stearyl dimethicone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
- A61K2800/21—Emulsions characterized by droplet sizes below 1 micron
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dispersion Chemistry (AREA)
- Cosmetics (AREA)
Abstract
The invention provides O/W emulsion composition, it is characterized in that: containing following compositions (A) ~ (G), and by high-pressure emulsification by emulsified particles miniaturization.The object of the present invention is to provide: utilizing high-pressure emulsification method by the O/W emulsion composition of emulsified particles miniaturization, can stably the salt form medicament of mixed electrolyte and the extremely excellent O/W emulsion composition of emulsion stability.(A) salt form medicament; (B) hydrophilic non-ionic surfactant; (C) N-long acyl aminoacid list salt; (D) alkali of two or more higher fatty acids and formation higher fatty acids soap; (E) higher alcohol; (F) oil content; (G) water.
Description
Technical field
The present invention relates to O/W emulsion composition.More specifically, relate to and utilizing high-pressure emulsification method by the O/W emulsion composition of emulsified particles miniaturization, stably can mix the O/W emulsion composition of salt form medicament and use the cosmetics of this emulsification composition.
Background technology
In recent years, people expect to have the H.D cosmetics for skin of moisture-keeping function, whitening function, antioxidation etc., and its exploitation of waiting in expectation.So, in the emulsification composition forming cosmetics for skin, in order to realize target high function or regulate the various object such as pH, thickening, people often the electrolyte such as organic acid and salt thereof such as mixed plant extract, citric acid, ascorbic acid, 4-methoxysalicylic acid as salt form medicament.
But, in emulsification composition, due to mixed electrolyte, there will be and such inherent problems that to decline with the stability of variations in temperature is changed in time for it.Particularly in the low viscous O/W emulsion composition of physicochemical property demonstrating aqueous solution, because mixing comprises electrolytical salt form medicament, and stability is extremely worsened.
About the destabilization of the above-mentioned emulsification composition caused owing to adding electrolyte, such as also on the books in patent documentation 1 or the document such as non-patent literature 1 and non-patent literature 2.
On the other hand, as by the O/W emulsion composition of high-pressure emulsification by emulsified particles miniaturization, disclose in patent documentation 2 ~ 4: the O/W emulsion composition of the low viscous physicochemical property with aqueous solution and the use sense of touch possessing white shape.Patent documentation 2 and 3 is the emulsifying technology using higher fatty acids soap substantially, and patent documentation 4 is the emulsifying technology using N-long acyl aminoacid list salt substantially.
But the O/W emulsion composition of patent documentation 2 ~ 4, it can obtain the combination of the surfactant of stable emulsification composition or oil content, their range of choice of combined amount etc. is narrow.Therefore, in order to realize target function, the various salt form medicaments of the combined amount desired by mixing may not be easy to make this emulsification composition stablize, as a rule all can with difficulty.
prior art document
patent documentation
Patent documentation 1: No. 4406498th, Japan Patent;
Patent documentation 2: No. 3398171st, Japan Patent;
Patent documentation 3: Japanese Unexamined Patent Publication 7-267814;
Patent documentation 4: Japanese Unexamined Patent Publication 9-301847.
non-patent literature
Non-patent literature 1: northern original text hero/Gu Zebang man work, " dispersion, emulsion type chemistry ", engineering books Co., Ltd., the 242nd page in 1979;
Non-patent literature 2: hide how refined son/Tian Duanyong core/infield then it/the bright work of the pretty hero/Tian Cunbo in large natural pond, " changing make-up product Ha Application De Block ッ Network ", daylight ケ ミ カ Le ズ Co., Ltd., nineteen ninety-five, the 201st page.
Summary of the invention
invent problem to be solved
The present inventor is in view of above-mentioned viewpoint, utilizing high-pressure emulsification method by the O/W emulsion composition of emulsified particles miniaturization, in order to obtain can the salt form medicament of stably mixed electrolyte, and the O/W emulsion composition of emulsion stability excellence, conduct in-depth research, found that: with (A) salt form medicament, (B) hydrophilic non-ionic surfactant, (C) N-long acyl aminoacid list salt, (D) alkali of two or more higher fatty acids and formation higher fatty acids soap, (E) higher alcohol, (F) oil content and the O/W emulsion composition of (G) water as essential component, have and stably can mix (A) salt form medicament, and the effect of emulsion stability excellence, thus complete the present invention.
The object of the present invention is to provide: utilizing high-pressure emulsification method by the O/W emulsion composition of emulsified particles miniaturization, can stably the salt form medicament of mixed electrolyte and the extremely excellent O/W emulsion composition of emulsion stability.
solve the method for problem
That is, the invention provides O/W emulsion composition, it is characterized in that: containing following compositions (A) ~ (G), and by high-pressure emulsification by emulsified particles miniaturization,
(A) salt form medicament;
(B) hydrophilic non-ionic surfactant;
(C) N-long acyl aminoacid list salt;
(D) alkali of two or more higher fatty acids and formation higher fatty acids soap;
(E) higher alcohol;
(F) oil content;
(G) water.
The present invention also provides cosmetics, it is characterized in that: comprise above-mentioned O/W emulsion composition.
invention effect
According to the present invention, can provide: utilizing high-pressure emulsification method by the O/W emulsion composition of emulsified particles miniaturization, can stably the salt form medicament of mixed electrolyte and the extremely excellent O/W emulsion composition of emulsion stability.
Detailed description of the invention
Below, the present invention is described in detail.
" (A) salt form medicament "
The salt form medicament mixed in the present invention is electrolyte, when mixing this salt form medicament, is make the ageing stability of O/W emulsion composition that the composition worsened occur as a rule.But in the present invention, even if when mixing salt form medicament, the ageing stability of this emulsification composition is also extremely excellent.
As the object lesson of salt form medicament, such as, preferably use: the salt of alkoxyl salicylic acid and derivant thereof; The salt of L-AA, L-AA phosphate ester, L-AA-2-sulfuric ester, AA 2G and their derivant; The alkali metal salt such as sodium salt, potassium salt, calcium salt of 4-methoxysalicylic acid or alkali salt or ammonium salt, amino acid salts; The potassium salt of glycyrrhizic acid, ammonium salt.Salt form medicament is present in the aqueous phase of O/W emulsion composition, is the composition playing objective function.
Relative to O/W emulsion composition total amount, combined amount preferably 0.01 ~ 5 quality % of salt form medicament, more preferably 0.5 ~ 3 quality %, most preferably is 1 ~ 3 quality %.
" (B) hydrophilic non-ionic surfactant "
In the present invention, hydrophilic non-ionic surfactant plays the composition of emulsifying agent effect.The hydrophilic non-ionic surfactant used in the present invention is not particularly limited, but preferably use POE alkyl ether type nonionic surfactant, specifically, preferred use POE(20) cetyl ether (the Japanese エ マ ルジョン Inc. of エ マ レ ッ Network ス 120), POE(25) cetyl ether (the Japanese エ マ ルジョン Inc. of エ マ レ ッ Network ス 125), POE(30) cetyl ether (the Japanese エ マ ルジョン Inc. of エ マ レ ッ Network ス 130), POE(30) docosyl ether (ニ ッ コ ー Le BB-30 daylight ケ ミ カ Le ズ Inc.), POE(20) one or more of docosyl ether (ニ ッ コ ー Le BB-20 daylight ケ ミ カ Le ズ Inc.) etc.
Relative to O/W emulsion composition total amount, combined amount preferably 0.01 ~ 1 quality % of hydrophilic non-ionic surfactant, more preferably 0.2 ~ 0.5 quality %, most preferably is 0.3 ~ 0.4 quality %.
" (C) N-long acyl aminoacid list salt "
In the present invention, N-long acyl aminoacid list salt is the composition playing emulsifying agent effect.The N-long acyl aminoacid list salt used in the present invention is not particularly limited; specifically, preferably use stearoyl-glutamic acid sodium (ア ミ ソ Off ト HS-11P(F) aginomoto Inc.), sodium lauroyl glutamate (ア ミ ソ Off ト LS-11 aginomoto Inc.), myristoyl glutamate potassium (ア ミ ソ Off ト MK-11 aginomoto Inc.), myristoyl glutamate sodium (ア ミ ソ Off ト MS-11 aginomoto Inc.) etc. one or more.
Relative to O/W emulsion composition total amount, combined amount preferably 0.01 ~ 1 quality % of N-long acyl aminoacid list salt, more preferably 0.2 ~ 0.5 quality %, most preferably is 0.3 ~ 0.4 quality %.
" alkali of the higher fatty acids that (D) is two or more and formation higher fatty acids soap "
In the present invention, the alkali of the higher fatty acids soap of two or more higher fatty acids and this higher fatty acids of formation is mixed with.That is, in the present invention, in formula, two or more higher aliphatic bronsted lowry acids and bases bronsted lowries is mixed with, and the diverse two or more higher fatty acids soap of the higher fatty acids formed after must neutralizing containing their.It should be noted that, the higher fatty acids soap be made up of two or more higher fatty acids can also be mixed, instead of by higher aliphatic bronsted lowry acids and bases bronsted lowry additional mixing in formula.
In the present invention, the diverse two or more higher fatty acids soap of higher fatty acids is the same with (C) with mentioned component (B), plays the effect of emulsifying agent.
The higher fatty acids used in the present invention is not particularly limited, specifically, preferably uses one or more of lauric acid, myristic acid, Palmic acid, stearic acid, behenic acid, isostearic acid etc.
In addition, the alkali used in the present invention is not particularly limited, as long as form higher fatty acids soap, but particularly preferably uses KOH.
As two or more higher fatty acids soaps, particularly preferably stearic acid potash soap and behenic acid potash soap.
Relative to O/W emulsion composition total amount, the combined amount of higher fatty acids, with two or more total gauge, preferably 0.1 ~ 5 quality %, more preferably 0.5 ~ 2 quality %, most preferably is 0.8 ~ 1.2 quality %.
About the combined amount of alkali, the molal quantity of the higher fatty acids that preferred mixing is two or more more than 60% molal quantity, relative to O/W emulsion composition total amount, preferably 0.02 ~ 1.6 quality %, more preferably 0.01 ~ 0.6 quality %, most preferably is 0.15 ~ 0.38 quality %.
" (E) higher alcohol "
The higher alcohol used in the present invention is the composition of the oil phase forming O/W emulsion composition, be not particularly limited, specifically, one or more of hexadecanol, stearyl alcohol, tadenan, myristyl alcohol, oleyl alcohol, cetostearyl alcohol, batilol, isooctadecanol are preferably used.
Relative to O/W emulsion composition total amount, combined amount preferably 0.1 ~ 5 quality % of higher alcohol, more preferably 1 ~ 3 quality %, most preferably is 1.5 ~ 2 quality %.
" (F) oil content "
The oil content used in the present invention is the composition of the oil phase forming O/W emulsion composition, is not particularly limited.
Specifically, can enumerate: the liquid fat such as American Avocado Tree oil, Camellia oil, turtle oil, macadimia nut oil, Semen Maydis oil, mink oil, olive oil, Oleum Brassicae campestris, egg oil, Oleum sesami, almond oil, Semen Tritici aestivi germ oil, Flos Camelliae Japonicae caul-fat, Oleum Ricini, Semen Lini oil, safflower oil, Oleum Gossypii semen, Radix Oenotherae erythrosepalae oil, perilla oil, soybean oil, Oleum Arachidis hypogaeae semen, Oleum Camelliae, Oleum Cocois (kayaoil), rice oil, Chinese wood oil, Japanese tung oil, Jojoba oil, germ oil, triglycerin, tricaprylin, three different tripalmitins;
The solid greases such as cocoa butter, Oleum Cocois (coconutoil), sclerosis Oleum Cocois, Petiolus Trachycarpi oil, palm-kernel oil, Japan wax's core oil, fixed oil, Japan wax, hardened castor oil;
The wax classes such as Cera Flava, candelilla wax, cotton wax, Brazil wax, Fructus Lauri nobilis wax, insect wax, montan wax, rice bran wax, lanoline, kapok wax, acetic acid lanoline, liquid lanolin, sugarcane wax, lanolin fatty isopropyl propionate, lauric acid hexyl ester, reduction lanoline, Jojoba wax, hard lanoline, shellac wax, POE lanoline alcohol ether, POE lanolin alcohol acetas, lanolin fatty acid macrogol ester, POE hydrogenated lanolin alcohol ether;
The hydrocarbon such as liquid paraffin, alpha-olefin oligomer, ceresine, Squalene, pristane, paraffin, ceresin, squalane, vaseline, microwax;
The silicone oil such as methyl polysiloxane, methyl phenyl silicone, amino modified siloxanes;
Isopropyl myristate, Cetyl octanoate, myristic acid octyldodecyl, isopropyl palmitate, butyl stearate, lauric acid hexyl ester, myristyl myristate, decyl oleate, dimethyl sad hexyl ester in the last of the ten Heavenly stems, lactic acid cetyl ester, Tetradecyl lactate, acetic acid lanoline, isocetyl stearate base ester, isostearic acid isocetyl ester, 12-hydroxy stearic acid cholesterol ester, two-2 ethyl hexanoic acid glycol ester, dipentaerythritol fatty acid ester, single isostearic acid N-alkyl diol ester, two capric acid DOPCP, malic acid two isooctadecane base ester, two-2-heptylundecanoic acid glycerides, three-2 ethyl hexanoic acid trimethylolpropane, three isostearic acid trimethylolpropanes, four-2 ethyl hexanoic acid pentaerythritol ester, three-2 ethyl hexanoic acid glyceride, three isostearic acid trimethylolpropanes, caproic acid cetyl-2-ethyl ester, Palmic acid 2-Octyl Nitrite, myristin, three-2-heptylundecanoic acid glycerides, Castor Oil Fatty Acid methyl ester, oleic oil alkene ester, cetostearyl alcohol, acetoglyceride, Palmic acid-2-heptylundecanoic base ester, diisopropyl adipate, N-lauroyl-Pidolidone-2-octyldodecyl, adipic acid two-2-heptylundecanoic base ester, Ethyl Lauroyl acid esters, Diisooctyl Sebacate, myristic acid-2-hexyl ester in the last of the ten Heavenly stems, Palmic acid-2-hexyl ester in the last of the ten Heavenly stems, adipic acid-2-hexyl ester in the last of the ten Heavenly stems, Dermol DIPS, succinic acid-2-Octyl Nitrite, ethyl acetate, butyl acetate, pentyl acetate, triethyl citrates etc. synthesize ester oil, can use one or more in above-mentioned oil content.
In the present invention, particularly preferred oil content is: liquid paraffin, alpha-olefin oligomer, squalane, vaseline, methyl polysiloxane, Cetyl octanoate.
The combined amount of oil content can suitably be determined, but relative to O/W emulsion composition total amount, preferably 0.1 ~ 10 quality %, more preferably 1 ~ 7 quality %, most preferably be 3 ~ 5 quality %.
" (G) water "
In the present invention, water is the composition of the aqueous phase forming O/W emulsion composition together with other water compositions, preferably uses ion exchange water.
The combined amount of water can suitably be determined, but relative to O/W emulsion composition total amount, preferably 50 ~ 90 quality %, more preferably 60 ~ 80 quality %, most preferably be 65 ~ 75 quality %.
In O/W emulsion composition of the present invention, except above-mentioned essential component, in the scope not undermining effect of the present invention, moistening effect can be improved by polyols blend or wetting agent.
Such as, as polyhydric alcohol, can enumerate: the dihydroxylic alcohols such as ethylene glycol, propylene glycol, 1,3-PD, 1,2-butanediol, 1,3 butylene glycol, BDO, 2,3-butanediol, 1,5-PD, 2-butylene-Isosorbide-5-Nitrae-glycol, hexanediol, ethohexadiol; The trihydroxylic alcohols such as glycerol, trimethylolpropane, 1,2,6-hexanetriol; The tetrahydroxylic alcohols such as tetramethylolmethane; The pentabasis alcohols such as xylitol; The polyol copolymer such as the hexahydroxylic alcohols such as sorbitol, mannitol, diethylene glycol, dipropylene glycol, 2,2'-ethylenedioxybis(ethanol)., polypropylene glycol, triglycerin, four glycerol, polyglycereol; The dihydroxylic alcohols alkyl ethers such as glycol monoethyl ether, ethylene glycol monoethyl ether, ethylene glycol monobutyl ether, ethylene glycol list phenyl ether, ethylene glycol ether, ethylene glycol list-2-methyl hexyl ether, ethylene glycol isoamyl oxide, ethylene glycol benzyl ether, glycol isopropyl ether, glycol dimethyl ether, ethylene glycol diethyl ether, butyl cellosolve; The dihydroxylic alcohols alkyl ethers such as diethylene glycol monomethyl ether, diethylene glycol monoethyl ether, diethylene glycol monobutyl ether, diethylene glycol dimethyl ether, diethyl carbitol, diethylene glycol dibutyl ether, diethylene glycol MEE, triethylene glycol monomethyl ether, 2,2'-ethylenedioxybis(ethanol). list ether, 2,2'-ethylenedioxybis(ethanol). list ether, propylene glycol monomethyl ether, dihydroxypropane single-ether, propylene glycol monobutyl ether, monoisopropyl ether, dipropylene glycol methyl ether, dipropylene glycol ether, dipropylene glycol butyl ether; The glycol ether esters such as ethylene glycol monomethyl ether acetate, ethylene glycol monoethylether acetate, ethylene glycol monomethyl ether acetate, ethylene glycol list phenyl ether acetate, ethylene glycol bisthioglycolate adipate ester, 3,6-Dioxa-1,2,7,8-octantetracarbonsaeure. ester, ethylene glycol monoethylether acetate, diethylene glycol monobutyl ether acetas, propylene glycol methyl ether acetate, propylene glycol monoethyl ether acetate, propylene glycol monopropyl ether acetas, propylene glycol list phenyl ether acetate; The glycerol monoalkyl ethers such as hexanol, selachyl alcohol, batilol; The sugar alcohols such as carbinol gone back by sorbitol, maltose alcohol, Fructus Hordei Germinatus three pool, mannitol, sucrose, erythritol, glucose, fructose, amylolysis sugar, maltose, xylose, amylolysis sugar; Glysolid, tetrahydrofurfuryl alcohol, POE tetrahydrofurfuryl alcohol, POP butyl ether, POPPOE butyl ether, methyl polypropylene glycerol aether, POP glycerin ether, POP glycerin ether phosphoric acid, POPPOE tetramethylolmethane ether etc.
As wetting agent, can enumerate: chondroitin sulfate, hyaluronic acid, mucoitinsulfuric acid, Carlow thujic acid, Atelocollagen, short chain soluble collagen, Fructus Rosae Normalis extracting solution, yarrow extract etc.
In addition, the various compositions mixed by usual cosmetic field can also be mixed in O/W emulsion composition of the present invention.Such as, as required, can suitably mixed-powder composition, water soluble polymer, UV absorbent, thickening agent, UV absorbent, metal ion sealer, ethanol, pH adjusting agent, skin-nourishing agent, antioxidant, antioxidation auxiliary agent, spice, pigment etc., utilize the conventional method of high-pressure emulsification to be prepared.
" miniaturization of the emulsified particles undertaken by high-pressure emulsification "
O/W emulsion composition of the present invention, the high pressure homogenisers such as preferred use high pressure homogenizer (Manton-Gaulin), method pressure kettle (Frechpress), high pressure nano homogenizer (Microfluidizer), carry out high-pressure emulsification to prepare to the mixed dispersion liquid containing above-mentioned essential component under the pressure of more than 30MPa.More preferably more than 50MPa.
In the present invention, the emulsifying particle diameter being carried out the emulsified particles of miniaturization by high-pressure emulsification is preferably 0.03 ~ 0.15
μm.
In addition, the viscosity of O/W emulsion composition of the present invention is low, preferably demonstrates the physicochemical property of aqueous solution.The range of viscosities using Brookfield viscometer (60rpm, 1 minute, 30 DEG C) to measure is preferably 5 ~ 50(mPas).
O/W emulsion composition of the present invention, even if when mixing salt form medicament, also can maintain stable emulsified state, therefore suitably can be used as cosmetics, the particularly cosmetics for skin of mixing salt form medicament.
Embodiment
Below, enumerate object lesson to further describe the present invention, but the present invention is not limited to these examples.It should be noted that, unless otherwise specified, then combined amount represents with " quality % ".
Use high pressure homogenisers, under the pressure of 55MPa, utilize conventional method to carry out high-pressure emulsification, the O/W emulsion composition of preparation shown in following table.
Afterwards, the O/W emulsion composition of gained is filled in sample cell, visualization just prepare after apparent condition, evaluate according to following standard.
Next, as the evaluation of ageing stability, preserve 4 weeks in the thermostat layer of 50 DEG C, the apparent condition of visualization after 4 weeks, evaluates according to following standard.
< evaluation criterion >
: outward appearance is unchanged, and stability is extremely excellent;
: observe cohesion or form emulsion;
: gelation.
[table 1]
| Embodiment 1 | Embodiment 2 | Embodiment 3 | Embodiment 4 | ||
| (1) | (D) stearic acid | 0.47 | 0.47 | 0.47 | 0.47 |
| (2) | (D) behenic acid | 0.53 | 0.53 | 0.53 | 0.53 |
| (3) | (E) stearyl alcohol | 0.28 | 0.28 | 0.28 | 0.28 |
| (4) | (E) tadenan | 1.22 | 1.22 | 1.22 | 1.22 |
| (5) | (F) methyl polysiloxane | 1 | 1 | 1 | 1 |
| (6) | (F) alpha-olefin oligomer | 4 | 4 | 4 | 4 |
| (7) | (G) ion exchange water (1) | 15 | 15 | 15 | 15 |
| (8) | (C) N-stearoyl-L-sodium | 0.3 | 0.3 | 0.3 | 0.3 |
| (9) | Glycerol | 8 | 8 | 8 | 8 |
| (10) | 1,3 butylene glycol | 4 | 4 | 4 | 4 |
| (11) | (D) potassium hydroxide | 0.175 | 0.175 | 0.175 | 0.175 |
| (12) | (G) ion exchange water (2) | Surplus | Surplus | Surplus | Surplus |
| (13) | (B) Polyoxyethylene cetyl ether (POE=25) | 0.3 | 0.3 | 0.3 | 0.3 |
| (14) | (A) 4-methoxysalicylic acid potassium salt | 3 | 1 | － | － |
| (15) | (A) AA 2G | － | － | 2 | － |
| (16) | (A) glycyrrhizic acid dipotassium | － | － | － | 0.5 |
| (17) | Ethanol | 2 | 2 | 2 | 2 |
| (18) | Disodium edetate | 0.01 | 0.01 | 0.01 | 0.01 |
| Outward appearance after just preparing | ○ | ○ | ○ | ○ | |
| Ageing stability (50 DEG C of 4W) | ○ | ○ | ○ | ○ | |
| Emulsifying particle diameter ( μM) (after just having prepared) | 0.06 | 0.06 | 0.06 | 0.06 | |
| Emulsifying particle diameter ( μm)(50℃·4Ｗ) | 0.08 | 0.07 | 0.08 | 0.06 |
< preparation method >
(1) ~ (6) are uniformly mixed at 80 DEG C.Be blended in the mixed liquor mixed liquor that heating for dissolving obtains at 70 DEG C by (7) ~ (11) while stirring, use high pressure homogenisers to carry out emulsifying under the pressure of 55MPa, be blended in while stirring afterwards (12) ~ mixed liquor of (16) in.
Result from " table 1 ": O/W emulsion composition of the present invention, even if when the conduct electrolytical salt form medicament 4-methoxysalicylic acid potassium salt of mixing 1 ~ 3 quality %, be also extremely stable O/W emulsion composition.Also known: even if when mixing the glycyrrhizic acid of other the AA 2G of salt form medicament, such as 2 quality % or 0.5 quality %, be also extremely stable O/W emulsion composition.
The cosmetics be made up of the O/W emulsion composition of gained, have the physicochemical property of aqueous solution, and after smearing on skin, are the cosmetics of the excellence use sense of touch playing white shape.
It should be noted that, the size of the emulsified particles in embodiment 1 and 2 is 0.05 ~ 0.1
μthe subparticle of m.
Below, O/W emulsion composition and the ageing stability of comparative example is shown.
The O/W emulsion composition of comparative example is prepared according to the preparation method of embodiment 1 and 2.
[table 2]
| Comparative example 1 | Comparative example 2 | Comparative example 3 | Comparative example 4 | Comparative example 5 | Comparative example 6 | Comparative example 7 | |
| (A) 4-methoxysalicylic acid potassium salt | － | 1 | 2 | 3 | 1 | 2 | 3 |
| (C) N-stearoyl-L-sodium | － | － | － | － | 0.3 | 0.3 | 0.3 |
| Glycerol | 8 | 8 | 8 | 8 | 8 | 8 | 8 |
| 1,3 butylene glycol | 4 | 4 | 4 | 4 | 4 | 4 | 4 |
| (D) potassium hydroxide | 0.18 | 0.18 | 0.18 | 0.18 | 0.18 | 0.18 | 0.18 |
| (D) stearic acid | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 |
| (D) behenic acid | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 |
| Stearyl alcohol | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 |
| (E) tadenan | 1.2 | 1.2 | 1.2 | 1.2 | 1.2 | 1.2 | 1.2 |
| (F) methyl polysiloxane | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| (F) alpha-olefin oligomer | 4 | 4 | 4 | 4 | 4 | 4 | 4 |
| Ethanol | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Disodium edetate | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| (G) ion exchange water | Surplus | Surplus | Surplus | Surplus | Surplus | Surplus | Surplus |
| Outward appearance after just preparing | ○ | × | × | × | ○ | ○ | ○ |
| Ageing stability (50 DEG C of 4W) | ○ | × | × | × | △ | △ | △ |
| Emulsifying particle diameter ( μM) (just after preparation) | 0.06 | － | － | － | 0.06 | 0.06 | 0.06 |
| Emulsifying particle diameter ( μm)(50℃·4Ｗ) | 0.06 | － | － | － | 0.09 | 0.11 | 0.18 |
In comparative example 1, owing to not mixing salt form medicament (A) 4-methoxysalicylic acid potassium salt, so ageing stability is no problem, emulsification composition is stablized.
But be mixed with in the comparative example 2 ~ 4 of salt form medicament (A) 4-methoxysalicylic acid potassium salt, not there is gelation after preparation in mixing (B) Polyoxyethylene cetyl ether (POE=25) and (C) N-stearoyl-L-sodium immediately.
On the other hand, comparative example 5 ~ 7 is by mixing (C) composition, and compared with comparative example 2 ~ 4, ageing stability slightly improves, but does not mix (B) composition, and change is in time observed cohesion or formed emulsion, has problems on ageing stability as product.
[table 3]
| Comparative example 2 | Comparative example 8 | Comparative example 9 | Comparative example 10 | Comparative example 11 | Comparative example 12 | Comparative example 13 | Comparative example 14 | Comparative example 15 | |
| (B) isostearic acid PEG-60 glyceride | 0.5 | ||||||||
| (B) POE (60) hardened castor oil | 0.5 | ||||||||
| (B) POE (100) hardened castor oil | 0.5 | ||||||||
| (B) stearic acid PEG-40 | 0.5 | ||||||||
| (B) POE (25) cetyl ether | 0.5 | 0.5 | 0.5 | ||||||
| POE (30) docosyl ether | 0.5 | ||||||||
| (A) 4-methoxysalicylic acid potassium salt | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 3 |
| Glycerol | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 |
| 1,3 butylene glycol | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 |
| (D) potassium hydroxide | 0.18 | 0.18 | 0.18 | 0.18 | 0.18 | 0.18 | 0.18 | 0.18 | 0.18 |
| (D) stearic acid | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 |
| (D) behenic acid | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 |
| (E) stearyl alcohol | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 |
| (E) tadenan | 1.2 | 1.2 | 1.2 | 1.2 | 1.2 | 1.2 | 1.2 | 1.2 | 1.2 |
| (F) methyl polysiloxane | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| (F) alpha-olefin oligomer | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 |
| Ethanol | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Disodium edetate | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| (G) ion exchange water | Surplus | Surplus | Surplus | Surplus | Surplus | Surplus | Surplus | Surplus | Surplus |
| Outward appearance after just preparing | × | × | × | × | × | ○ | ○ | ○ | ○ |
| Ageing stability (50 DEG C of 4W) | × | × | × | × | × | △ | △ | △ | △ |
| Emulsifying particle diameter ( μM) (after just having prepared) | － | － | － | － | － | 0.06 | 0.06 | 0.06 | 0.06 |
| Emulsifying particle diameter ( μm)(50℃?4Ｗ) | － | － | － | － | － | 0.18 | 0.22 | 0.22 | 0.34 |
Be mixed with comparative example 2, the comparative example 8 ~ 15 of salt form medicament (A) 4-methoxysalicylic acid potassium salt, owing to not mixing (C) N-stearoyl-L-sodium composition, therefore have problems on ageing stability.
It should be noted that, in comparative example 12 ~ 15, by mixing POE alkyl ether type nonionic surfactant, compare with comparative example 8 ~ 11 with comparative example 2, ageing stability slightly improves, but not mixing (C) composition, change is in time observed cohesion or is formed emulsion, has problems on ageing stability as product.
[table 4]
| Comparative example 1 | Comparative example 7 | Comparative example 16 | Comparative example 17 | |
| (D) stearic acid | 0.5 | 0.5 | － | 1 |
| (D) behenic acid | 0.5 | 0.5 | 1 | － |
| (D) potassium hydroxide | 0.18 | 0.18 | 0.16 | 0.19 |
| (A) 4-methoxysalicylic acid potassium salt | － | 3 | 3 | 3 |
| Glycerol | 8 | 8 | 8 | 8 |
| 1,3 butylene glycol | 4 | 4 | 4 | 4 |
| (C) N-stearoyl-L-sodium | 0.3 | 0.3 | 0.3 | 0.3 |
| (E) stearyl alcohol | 0.3 | 0.3 | 0.3 | 0.3 |
| (E) tadenan | 1.2 | 1.2 | 1.2 | 1.2 |
| (F) methyl polysiloxane | 1 | 1 | 1 | 1 |
| (F) alpha-olefin oligomer | 4 | 4 | 4 | 4 |
| Ethanol | 2 | 2 | 2 | 2 |
| Disodium edetate | 0.01 | 0.01 | 0.01 | 0.01 |
| (G) ion exchange water | Surplus | Surplus | Surplus | Surplus |
| Outward appearance after just preparing | ○ | ○ | ○ | × |
| Ageing stability (50 DEG C of 4W) | ○ | △ | △ | × |
| Emulsifying particle diameter ( μM) (after just having prepared) | 0.06 | 0.06 | 0.08 | － |
| Emulsifying particle diameter ( μm)(50℃·4Ｗ) | 0.06 | 0.18 | 0.38 | － |
In comparative example 1, owing to not mixing salt form medicament (A) 4-methoxysalicylic acid potassium salt, so ageing stability is no problem, emulsification composition is stablized.
On the other hand, be mixed with the comparative example 7,16 ~ 17 of salt form medicament (A) 4-methoxysalicylic acid potassium salt, due to not mixing (B) Polyoxyethylene cetyl ether (POE=25), ageing stability have problems.
[table 5]
In comparative example 1, owing to not mixing salt form medicament (A) 4-methoxysalicylic acid potassium salt, ageing stability is no problem, and emulsification composition is stablized.Comparative example 7 and 18 ~ 19 is mixing (B) Polyoxyethylene cetyl ether (POE=25) composition not, and ageing stability has problems.Comparative example 15 and 20 ~ 21 is mixing (C) N-stearoyl-L-sodium composition not, and ageing stability has problems.
In contrast, embodiments of the invention 1 and embodiment 2, by mixing (B) and (C) composition, even if mixing salt form medicament (A) 4-methoxysalicylic acid potassium salt, ageing stability is also no problem.
industrial applicability
According to the present invention, can provide: utilizing high-pressure emulsification method by the O/W emulsion composition of emulsified particles miniaturization, can stably mix salt form medicament and the extremely excellent O/W emulsion composition of emulsion stability.
O/W emulsion composition of the present invention is applicable to the cosmetics mixing salt form medicament.
Claims (3)
1. O/W emulsion composition, is characterized in that: containing following compositions (A) ~ (G), and by the high-pressure emulsification under the pressure of more than 50MPa, emulsified particles to be micronized into emulsifying particle diameter be 0.03 ~ 0.15
μm scope, has the physicochemical property of the low aqueous solution of viscosity, and ageing stability is excellent,
(A) the 4-methoxysalicylic acid potassium salt of 1 ~ 3 quality %;
(B) POE alkyl ether type nonionic surfactant;
(C) stearoyl-glutamic acid sodium;
(D) alkali of two or more higher fatty acids and formation higher fatty acids soap;
(E) higher alcohol;
(F) oil content;
(G) water.
2. O/W emulsion composition according to claim 1, is characterized in that: the physicochemical property of the aqueous solution that above-mentioned viscosity is low is the range of viscosities using Brookfield viscometer to measure under 60rpm, 1 minute, 30 DEG C conditions is 5 ~ 50mPas.
3. cosmetics, is characterized in that: comprise the O/W emulsion composition described in claim 1 or 2.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2010-263572 | 2010-11-26 | ||
| JP2010263572 | 2010-11-26 | ||
| JP2011209211A JP5083993B2 (en) | 2010-11-26 | 2011-09-26 | Oil-in-water emulsion composition |
| JP2011-209211 | 2011-09-26 | ||
| PCT/JP2011/072859 WO2012070315A1 (en) | 2010-11-26 | 2011-10-04 | Oil-in-water type emulsion composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103313694A CN103313694A (en) | 2013-09-18 |
| CN103313694B true CN103313694B (en) | 2016-03-23 |
Family
ID=46145673
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201180054795.9A Active CN103313694B (en) | 2010-11-26 | 2011-10-04 | O/W emulsion composition |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US8821905B2 (en) |
| EP (1) | EP2644184B1 (en) |
| JP (1) | JP5083993B2 (en) |
| KR (1) | KR101256785B1 (en) |
| CN (1) | CN103313694B (en) |
| ES (1) | ES2710005T3 (en) |
| HK (1) | HK1185557A1 (en) |
| TW (1) | TWI488647B (en) |
| WO (1) | WO2012070315A1 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5570442B2 (en) * | 2011-01-24 | 2014-08-13 | 株式会社シャネル化粧品技術開発研究所 | Oil-in-water emulsion composition and method for producing the same |
| JP2015205874A (en) * | 2014-04-11 | 2015-11-19 | 御木本製薬株式会社 | oil-in-water emulsion composition |
| JP7412068B2 (en) * | 2016-12-16 | 2024-01-12 | 株式会社 資生堂 | oil-in-water composition |
| JP7431156B2 (en) * | 2018-06-20 | 2024-02-14 | 株式会社 資生堂 | Oil-in-water emulsion composition and method for producing the same |
| FR3083095B1 (en) * | 2018-06-28 | 2020-06-05 | L'oreal | COMPOSITION COMPRISING A SATURATED FATTY ALCOHOL, AT LEAST ONE ANIONIC FATTY CHAIN SURFACTANT, A POLYOL, AND AT LEAST ONE SILICONE OIL |
| WO2023100683A1 (en) * | 2021-12-02 | 2023-06-08 | 株式会社 資生堂 | Oil-in-water emulsion cosmetic |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3398171B2 (en) | 1993-03-15 | 2003-04-21 | 株式会社資生堂 | Oil-in-water emulsion composition |
| JPH07267814A (en) | 1994-03-29 | 1995-10-17 | Shiseido Co Ltd | Toilet water type emulsified composition |
| JP3434115B2 (en) * | 1996-02-29 | 2003-08-04 | 株式会社資生堂 | Emulsified cosmetic |
| JPH09301847A (en) * | 1996-03-15 | 1997-11-25 | Shiseido Co Ltd | Low viscosity water in oil-type emulsified composition and dermal agent for external use using the same |
| KR100563583B1 (en) * | 1997-07-17 | 2006-03-30 | 가부시키가이샤 시세이도 | O/w/o type multiphase emulsion |
| JP4406498B2 (en) | 2000-07-10 | 2010-01-27 | ライオン株式会社 | Skin cosmetics |
| JP2006327952A (en) * | 2005-05-24 | 2006-12-07 | Shiseido Co Ltd | Oil in water type emulsion composition and method for producing the same |
| JP5147098B2 (en) * | 2005-06-03 | 2013-02-20 | マルホ株式会社 | Liquid crystal emulsified composition |
| JP5342102B2 (en) * | 2006-07-04 | 2013-11-13 | 昭和電工株式会社 | Emulsion composition |
| JP5203623B2 (en) * | 2007-03-30 | 2013-06-05 | 株式会社コーセー | Oil-in-water emulsified cosmetic |
| JP2009196980A (en) * | 2008-01-22 | 2009-09-03 | Kao Corp | Melanin synthesis inhibitor and whitening cosmetic |
| JP4767352B1 (en) * | 2010-03-17 | 2011-09-07 | 株式会社 資生堂 | Emulsified composition |
-
2011
- 2011-09-26 JP JP2011209211A patent/JP5083993B2/en active Active
- 2011-09-30 TW TW100135409A patent/TWI488647B/en not_active IP Right Cessation
- 2011-10-04 WO PCT/JP2011/072859 patent/WO2012070315A1/en active Application Filing
- 2011-10-04 CN CN201180054795.9A patent/CN103313694B/en active Active
- 2011-10-04 ES ES11842766T patent/ES2710005T3/en active Active
- 2011-10-04 EP EP11842766.5A patent/EP2644184B1/en active Active
- 2011-10-04 US US13/877,350 patent/US8821905B2/en active Active
- 2011-10-04 KR KR1020137005500A patent/KR101256785B1/en active IP Right Grant
-
2013
- 2013-11-21 HK HK13113022.0A patent/HK1185557A1/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| JP2012126705A (en) | 2012-07-05 |
| KR101256785B1 (en) | 2013-04-25 |
| EP2644184A1 (en) | 2013-10-02 |
| CN103313694A (en) | 2013-09-18 |
| EP2644184A4 (en) | 2015-07-15 |
| US8821905B2 (en) | 2014-09-02 |
| US20130189335A1 (en) | 2013-07-25 |
| ES2710005T3 (en) | 2019-04-22 |
| JP5083993B2 (en) | 2012-11-28 |
| EP2644184B1 (en) | 2019-01-02 |
| KR20130028987A (en) | 2013-03-20 |
| HK1185557A1 (en) | 2014-02-21 |
| TWI488647B (en) | 2015-06-21 |
| TW201231068A (en) | 2012-08-01 |
| WO2012070315A1 (en) | 2012-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103313694B (en) | O/W emulsion composition | |
| EP2127635B1 (en) | Oil-in-water type emulsion composition | |
| JP5047369B2 (en) | Method for producing O / W fine emulsion external preparation | |
| TWI503126B (en) | Liquid cosmetic | |
| TW201615177A (en) | Elastic jelly-like composition | |
| JP6860297B2 (en) | Oil-in-water emulsified external preparation composition | |
| CN102378625A (en) | External preparation for skin | |
| JP2008231010A (en) | External preparation for skin | |
| JP6036188B2 (en) | Cleansing cream | |
| JP2012031068A (en) | Ufenamate-containing skin care preparation | |
| KR20140012695A (en) | Manufacturing method for o/w emulsion composition | |
| CN103096871B (en) | Oil-in-water type cosmetic | |
| JP6628580B2 (en) | Hair cosmetic composition | |
| WO2021123861A1 (en) | Oil-in-water emulsified cosmetic | |
| TWI614334B (en) | Viscous detergent composition | |
| KR102394035B1 (en) | Ceramide-containing cosmetic composition using high-pressure homogenizer and method for manufacturing the same | |
| WO2020213660A1 (en) | O/d-type emulsion composition containing glycyrrhetinic acid, and oil-in-water-type emulsion composition | |
| JP2002145733A (en) | Solid water-in-oil type emulsion cosmetic | |
| KR20230124615A (en) | aqueous emulsion | |
| TW202007389A (en) | Aerosol type cosmetic | |
| CN100369600C (en) | Oil-in-water type emulsion composition and its preparing method | |
| KR20240111233A (en) | Cosmetic composition containing capsules and method of preparing the same | |
| CN118236273A (en) | Composition with lamellar liquid crystal structure | |
| CN117398300A (en) | Oil-in-water type emulsified cosmetic | |
| WO2022136903A1 (en) | Oil-in-water emulsified make-up remover |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1185557 Country of ref document: HK |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1185557 Country of ref document: HK |